Skip to main content
OpenTrials
Completed

NCT Number: NCT04600609

Examining the Experiences of Children With Blood Disorders

This is a 3-phase mixed methods study design. A literature review (Phase 1) has been completed to determine the areas of exploration and to identify challenges faced and the impact of the blood disorder on pediatric patients. Based on Phase 1, Phases 2 and 3, as proposed in this study, will be completed and will include interviews of patients diagnosed with bleeding and thrombotic disorders (phase 2). The interviews will be individual, semi-structured, and consist of open-ended questions to elicit unbiased and in-depth responses to gain an understanding of participant's perspectives on themes predetermined in the study design phase.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Texas Southwestern Medical Center

Dallas, Texas, 75235, United States

About this study

The purpose of this study is to explore the experiences of pediatric patients with blood disorders, specifically thrombotic, including venous thromboembolism (VTE), and hemostatic or bleeding disorders. The information gleaned from this study will help identify specific challenges faced by patients with hemostatic and thrombotic disorders - information that is necessary to develop impactful, evidence-based solutions to support patients with hemostatic and thrombotic disorders cope with the physical, emotional, and psychological impact of blood disorders. Participants with blood disorders in this study will participate in open-ended, semi-structured interviews with a study investigator focusing on the psychosocial experiences of patients with diagnosis and treatment of their underlying disorder and the understanding of their diagnosis. Female participants additionally will be asked questions about the unique effects of heavy menstrual bleeding, either from their underlying blood disorder or secondary to anticoagulation, on similar aspects of the impact of having a blood disorder. Validated questionnaires will be completed to obtain concurrent quantitative data. The interviews will be recorded and transcribed. Participation is complete after the interview has finished; participants will continue to receive standard of care treatment during and beyond the study period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients will be eligible to participate if they are between the ages of 12 and 21 years of age, English speaking and have a formal diagnosis of a hemostatic or thrombotic disorder. For thrombotic disorder patients, an additional eligibility criterion will be to include participants within 1 year of diagnosis.

Exclusion criteria

  • Patients will be excluded if they do not have access to the technology needed to participate in a virtual interview visit (by telephone).

Treatment and study plan

Primary outcomes

  1. Quality of life assessment

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Effect of blood disorder diagnosis on quality of life will be measured using Pediatric Quality of Life Questionnaire, Menorrhagia Impact Questionnaire, and Godin Physical Activity Questionnaire

  2. Patient confidence assessment

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Patient confidence in managing blood disorder and recognizing emergencies will be assessed using a semi-structured interview with the patient

  3. Quality of care assessment

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Impressions of quality of care received in a specialized bleeding disorders and thrombosis clinic will be assessed using a semi-structured interview with the patient

  4. Implications on the future for the patient with the bleeding disorder

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Patient's reaction to the diagnosis and its impact on their future will be assessed using a semi-structured interview with the patient

Secondary outcomes

  1. Depression screening

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Screening completed using PHQ-9 questionnaire

  2. Quality of life screening

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Screening completed using Peds QOL questionnaire

  3. Menorrhagia screening for participants with bleeding disorders

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Screening completed using Menorrhagia impact questionnaire

  4. Dalhousie Dypsnea screening for participants with clots

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Screening completed using Dalhousie Dypsnea questionnaire

  5. Physical activity screening

    Time frame: Within 1 year of diagnosis for clot patients; after formal diagnosis for bleeding disorder patients

    Screening completed using Godin Physical Activity questionnaire

Sponsors and collaborators

Lead sponsor

University of Texas Southwestern Medical Center

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 23, 2020
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.